BR112023020026A2 - Composição para prevenir ou tratar doença renal crônica compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho - Google Patents

Composição para prevenir ou tratar doença renal crônica compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho

Info

Publication number
BR112023020026A2
BR112023020026A2 BR112023020026A BR112023020026A BR112023020026A2 BR 112023020026 A2 BR112023020026 A2 BR 112023020026A2 BR 112023020026 A BR112023020026 A BR 112023020026A BR 112023020026 A BR112023020026 A BR 112023020026A BR 112023020026 A2 BR112023020026 A2 BR 112023020026A2
Authority
BR
Brazil
Prior art keywords
composition
klotho
kidney disease
chronic kidney
compounds
Prior art date
Application number
BR112023020026A
Other languages
English (en)
Portuguese (pt)
Inventor
Ju Jung Dong
Original Assignee
Klotho Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220040453A external-priority patent/KR102463786B1/ko
Application filed by Klotho Sciences filed Critical Klotho Sciences
Publication of BR112023020026A2 publication Critical patent/BR112023020026A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023020026A 2021-04-01 2022-04-01 Composição para prevenir ou tratar doença renal crônica compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho BR112023020026A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210042955 2021-04-01
KR1020220040453A KR102463786B1 (ko) 2021-04-01 2022-03-31 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
PCT/KR2022/004706 WO2022211574A1 (ko) 2021-04-01 2022-04-01 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
BR112023020026A2 true BR112023020026A2 (pt) 2024-01-23

Family

ID=83456608

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020026A BR112023020026A2 (pt) 2021-04-01 2022-04-01 Composição para prevenir ou tratar doença renal crônica compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho

Country Status (8)

Country Link
US (1) US12691102B2 (enExample)
EP (1) EP4317140A4 (enExample)
JP (1) JP7728030B2 (enExample)
CN (1) CN117157280B (enExample)
AU (2) AU2022248891A1 (enExample)
BR (1) BR112023020026A2 (enExample)
CA (1) CA3213910A1 (enExample)
WO (1) WO2022211574A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
CA2783555A1 (en) * 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
KR101372721B1 (ko) * 2010-06-18 2014-03-14 이화여자대학교 산학협력단 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
WO2016176473A1 (en) * 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR101770310B1 (ko) * 2015-08-24 2017-08-24 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2018087132A1 (en) * 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3611521B1 (en) 2018-08-16 2026-05-27 GE Vernova Technology GmbH Apparatus for monitoring a condition of an electrical power transmission medium
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
KR20200145909A (ko) 2019-06-20 2020-12-31 주식회사 레이지소사이어티 면도날 자동주문 장치
WO2021066608A1 (ko) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2022211574A1 (ko) 2022-10-06
AU2025202595A1 (en) 2025-05-01
AU2022248891A1 (en) 2023-10-26
CA3213910A1 (en) 2022-10-06
AU2022248891A9 (en) 2023-11-09
EP4317140A4 (en) 2025-04-09
CN117157280B (zh) 2026-07-21
JP2024512813A (ja) 2024-03-19
US12691102B2 (en) 2026-07-28
US20240216341A1 (en) 2024-07-04
JP7728030B2 (ja) 2025-08-22
CN117157280A (zh) 2023-12-01
EP4317140A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112018069732A2 (pt) métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
BR112022004175A2 (pt) Tratamento de encefalopatia de syngap1
BR112015022340A2 (pt) método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112018076485A8 (pt) Carotenoides microbianos afetando a composição microbiana do intestino
MA46366B1 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015024537A8 (pt) uso de um ou mais (i) ciclofosfamida, (ii) metformina e (iii) pelo menos um outro agente no tratamento de câncer, combinação, ciclofosfamida, metformina ou um agente
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp
BR112013024368A8 (pt) Combinações de composto ativo
BR112023019984A2 (pt) Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
BR112017011916A2 (pt) agente para tratamento de deformação de cabelo
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos